Moderna Inc. reported strong second-quarter 2026 financial results, generating revenue of USD 145.00 million against a consensus estimate of USD 102.93 million, representing a significant beat. The company also posted earnings per share (EPS) of USD -1.97, which exceeded the estimated loss of USD -2.03 by USD 0.06. Despite remaining in a loss-making position, the revenue growth indicates improving commercial performance and validates the company's pipeline valuation. The stock was trading at USD 182.11 on September 23, 2026, which is below its 52-week high but reflects a substantial discount to analyst price targets. MarketBeat reports an average price target of USD 76.72 with a Hold consensus rating, creating a valuation debate where the current market price sits nearly 58% above the average target. This discrepancy positions the upcoming oncology data presentation as a critical test for the company's narrative. Moderna is preparing to present Phase 3 data for its melanoma candidate, intismeran (autogene), at the ESMO Congress on October 24, 2026. The presentation will cover updates on personalized therapies for pancreatic and lung cancer as well, providing near-term evidence points for the oncology pipeline. An investor webcast is scheduled for the same date to discuss these developments.